A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients (Q35101968)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Akseli Hemminki

11

object named as

Akseli Hemminki

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

David T. Curiel

14

object named as

David T Curiel

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

10

object named as

Gene P Siegal

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Kenneth H Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael J Ryan

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

James E Estep

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Brock M Miniard

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Thomas L Rudge

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

James O Peggins

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Trevor L Broadt

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Minghui Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Meredith A Preuss

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Raymond D Harris

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Rosemarie Aurigemma

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ronald D Alvarez

15

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

23 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Human Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

821-828

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Advancements in adenoviral based virotherapy for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

9 July 2018

Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135257

27 September 2018

Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21171861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21171861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21171861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/HUM.2010.180

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35101968&oldid=2033539869"